Prevalence of chronic HBV infection in pregnant woman attending antenatal care in a tertiary hospital in Mwanza, Tanzania: a cross-sectional study.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
05 Jun 2020
Historique:
received: 14 11 2019
accepted: 15 05 2020
entrez: 7 6 2020
pubmed: 7 6 2020
medline: 8 7 2020
Statut: epublish

Résumé

Tanzania has a high prevalence (7.17%) of chronic hepatitis B infection. Mother to Child transmission is very common, resulting in high rate of chronic infections. Currently, there is no screening program for HBV in pregnant women. This study investigated the prevalence and risk factors for chronic HBV infection in pregnant women in a tertiary hospital in Mwanza, Tanzania. Seven hundred and forty-three women attending antenatal care and/or delivering at the Bugando Medical Centre were enrolled. All answered a questionnaire on sociodemographic and other risk factors and were tested for HBsAg using a rapid test. In HBsAg positive mothers, maternal blood and umbilical cord blood samples collected after delivery were analyzed for serological (HBsAg, HBeAg and anti-HBe) and virologic (HBV-DNA viral load and genotype) markers. All their babies were vaccinated within 24 h of delivery. The children were followed up at 3 years of age. Data was analyzed using the Mann-Whitney U-test, independent sample T-test and logistic regression. Of the 743 participants, 22 (3%) were positive for HBsAg, and 2 (9%) had detectable HBe-antigen. Low condom use was the only statistically significant risk factor for chronic HBV infection (OR = 3.514, 95%CI = 1.4-8.0). Of 14 maternal blood samples genotyped, 10 (71%) were genotype A and 4 (29%) were genotype D. HBV-DNA was detected in 21/22 samples, with a median of 241 IU/ml (range: 27.4-25.9 × 10 This cohort of pregnant women showed a lower-intermediate prevalence of HBV of 3%. In the 3 years follow-up only 1 out of 7 children showed evidence of chronic HBV infection. The child's mother with high viral load (25.9 × 10

Sections du résumé

BACKGROUND BACKGROUND
Tanzania has a high prevalence (7.17%) of chronic hepatitis B infection. Mother to Child transmission is very common, resulting in high rate of chronic infections. Currently, there is no screening program for HBV in pregnant women. This study investigated the prevalence and risk factors for chronic HBV infection in pregnant women in a tertiary hospital in Mwanza, Tanzania.
METHODS METHODS
Seven hundred and forty-three women attending antenatal care and/or delivering at the Bugando Medical Centre were enrolled. All answered a questionnaire on sociodemographic and other risk factors and were tested for HBsAg using a rapid test. In HBsAg positive mothers, maternal blood and umbilical cord blood samples collected after delivery were analyzed for serological (HBsAg, HBeAg and anti-HBe) and virologic (HBV-DNA viral load and genotype) markers. All their babies were vaccinated within 24 h of delivery. The children were followed up at 3 years of age. Data was analyzed using the Mann-Whitney U-test, independent sample T-test and logistic regression.
RESULTS RESULTS
Of the 743 participants, 22 (3%) were positive for HBsAg, and 2 (9%) had detectable HBe-antigen. Low condom use was the only statistically significant risk factor for chronic HBV infection (OR = 3.514, 95%CI = 1.4-8.0). Of 14 maternal blood samples genotyped, 10 (71%) were genotype A and 4 (29%) were genotype D. HBV-DNA was detected in 21/22 samples, with a median of 241 IU/ml (range: 27.4-25.9 × 10
CONCLUSION CONCLUSIONS
This cohort of pregnant women showed a lower-intermediate prevalence of HBV of 3%. In the 3 years follow-up only 1 out of 7 children showed evidence of chronic HBV infection. The child's mother with high viral load (25.9 × 10

Identifiants

pubmed: 32503443
doi: 10.1186/s12879-020-05096-2
pii: 10.1186/s12879-020-05096-2
pmc: PMC7275503
doi:

Substances chimiques

DNA, Viral 0
Hepatitis B Antibodies 0
Hepatitis B Surface Antigens 0
Hepatitis B e Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395

Références

Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Hepatol Res. 2007 Jul;37(s1):S9-S19
pubmed: 17627641
Clin Vaccine Immunol. 2010 Dec;17(12):1836-41
pubmed: 20943880
PLoS One. 2017 Jul 21;12(7):e0181267
pubmed: 28732085
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):17
pubmed: 29296152
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
Int J Med Sci. 2005;2(1):50-57
pubmed: 15968340
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Iran Red Crescent Med J. 2015 Jul 22;17(7):e20598
pubmed: 26421168
BMC Infect Dis. 2017 Sep 11;17(1):618
pubmed: 28893207
J Pediatric Infect Dis Soc. 2013 Dec;2(4):320-6
pubmed: 24363930
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):18
pubmed: 29296153
World J Gastroenterol. 2016 Oct 21;22(39):8720-8734
pubmed: 27818588
J Virol Methods. 2005 Jun;126(1-2):207-13
pubmed: 15847939
Int J Infect Dis. 2010 Nov;14(11):e941-53
pubmed: 20674432
Tanzan J Health Res. 2014 Jan;16(1):9-15
pubmed: 26867267
J Med Virol. 2008 Jul;80(7):1160-70
pubmed: 18461609
Lancet Glob Health. 2015 Jul;3(7):e358-9
pubmed: 26087980
J Trop Med. 2018 Jan 30;2018:4239646
pubmed: 29666656
J Gen Virol. 2017 May;98(5):1048-1057
pubmed: 28537543
Int J Gynaecol Obstet. 2018 Apr;141(1):126-132
pubmed: 29315536
N Engl J Med. 2016 Jun 16;374(24):2324-34
pubmed: 27305192
East Afr Med J. 2006 Feb;83(2):91-4
pubmed: 16708880
Dig Liver Dis. 2019 Jun;51(6):864-869
pubmed: 30528568
BMC Infect Dis. 2014 Mar 01;14:118
pubmed: 24580859
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Ann Trop Paediatr. 2010;30(2):129-36
pubmed: 20522299
BMC Pregnancy Childbirth. 2017 Apr 7;17(1):109
pubmed: 28388879
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):900-909
pubmed: 29132759

Auteurs

Karin Geffert (K)

Medical Mission Institute, Wuerzburg, Germany.

Tongai G Maponga (TG)

Division of Medical Virology, University of Stellenbosch, Faculty of Medicine and Health Sciences, Francie van Zijl Avenue, Tygerberg Cape Town, South Africa.

Shimba Henerico (S)

Division of Medical Virology, University of Stellenbosch, Faculty of Medicine and Health Sciences, Francie van Zijl Avenue, Tygerberg Cape Town, South Africa.
Bugando Medical Centre, Mwanza, Tanzania.

Wolfgang Preiser (W)

Division of Medical Virology, University of Stellenbosch, Faculty of Medicine and Health Sciences, Francie van Zijl Avenue, Tygerberg Cape Town, South Africa.

Stella Mongella (S)

Catholic University of Health and Allied Health Sciences, Mwanza, Tanzania.

August Stich (A)

Medical Mission Institute, Wuerzburg, Germany.

Samuel Kalluvya (S)

Bugando Medical Centre, Mwanza, Tanzania.

Andreas Mueller (A)

Medical Mission Institute, Wuerzburg, Germany.

Christa Kasang (C)

Medical Mission Institute, Wuerzburg, Germany. christa.kasang@medmissio.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH